Dyslipidaemia – Global Clinical Trial Landscape (2023)

Dyslipidaemia, characterized by abnormal blood lipids, has posed a growing global health concern over the past three decades, significantly increasing the risk of ischemic heart disease. Elevated LDL, total cholesterol, and triglycerides, along with low HDL, are major cardiovascular risk factors. Familial hypercholesterolemia, affecting 1 in 300 individuals globally, heightens this risk. Atherogenic dyslipidaemia, prevalent in diabetes and metabolic syndrome, further escalates cardiovascular risk.

Lifestyle modifications are the first-line treatment, emphasizing dietary changes and increased physical activity, with a focus on vegetables, fruits, whole grains, and aerobic exercise. Statins, which inhibit HMG-CoA reductase, are commonly used for dyslipidaemia.

Regional variations in hypercholesterolemia rates are observed, with Europe and America having higher rates. Asia Pacific (APAC) leads in dyslipidaemia research, with over 65% of trials, driven by Mainland China and South Korea. Various pharmaceutical companies have developed medications, including statins and innovative therapies like small interfering RNA (siRNA) and antibodies.

In summary, dyslipidaemia is a growing global health challenge. Lifestyle modifications and statins are key approaches, while regional strategies are needed. While APAC is at the forefront of research, gain insight into pharmaceutical companies' continued new treatment developments and innovative therapies.